0
selected
-
1.
Cellular and Molecular Targets of Resveratrol on Lymphoma and Leukemia Cells.
Frazzi, R, Guardi, M
Molecules (Basel, Switzerland). 2017;(6)
Abstract
Resveratrol (RSV) is a well known chemopreventive molecule featuring anti-cancer properties. Our paper describes the main molecular targets of RSV linked to its antiproliferative activity on lymphoma and leukemia experimental models. It discusses further the most recent and most promising among these molecular targets for a translational application.
-
2.
Neurologic Manifestations of Blood Dyscrasias.
Couriel, DR, Ricker, H, Steinbach, M, Lee, CJ
Hematology/oncology clinics of North America. 2016;(4):723-31
Abstract
Neurologic manifestations are common in blood diseases, and they can be caused by the hematologic disorder or its treatment. This article discusses hematologic diseases in adult patients, and categorizes them into benign and malignant conditions. The more common benign hematologic diseases associated with neurologic manifestations include anemias, particularly caused by B12 deficiency and sickle cell disease, and a variety of disorders of hemostasis causing bleeding or thrombosis, including thrombotic microangiopathy. Malignant conditions like multiple myeloma, leukemias, and lymphomas can have neurologic complications resulting from direct involvement, or caused by the different therapies to treat these cancers.
-
3.
Extrahepatic manifestations of HCV.
Grignoli, R, Goossens, N, Negro, F
Minerva gastroenterologica e dietologica. 2015;(1):31-8
Abstract
The hepatic consequences of an infection with the hepatitis C virus (HCV) are well recognised, but extrahepatic manifestations of HCV may be just as severe. Here we have reviewed various extrahepatic manifestations of HCV such as mixed cryoglobulinemia, lymphoma, metabolic features and neurologic consequences and we discuss pathogenesis and management of these clinical problems. We concluded with important aspects of therapy with novel anti-HCV agents and its effects on extrahepatic manifestations.
-
4.
[Changes in nutrition metabolism of lymphoma after treatment and the nutritional supports].
Wu, M, Zhu, J
Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae. 2014;(4):446-9
Abstract
The incidence of lymphoma has increased annually. The nutrition status of lymphoma patients influences their quality of life and even the tolerance to treatment. This review summarizes the resting energy expenditure of untreated lymphoma patients, influence of chemotherapy and bone marrow transplantation on nutrition status, and individualized nutrition support for these patients.
-
5.
Kidney involvement in leukemia and lymphoma.
Luciano, RL, Brewster, UC
Advances in chronic kidney disease. 2014;(1):27-35
Abstract
Leukemia and lymphoma are hematologic malignancies that can affect any age group. Disease can be aggressive or indolent, often with multiorgan system involvement. Kidney involvement in leukemia and lymphoma can be quite extensive. Acute kidney injury (AKI) is quite prevalent in these patients, with prerenal and acute tubular necrosis being the most common etiologies. However other prerenal, intrinsic, and obstructive etiologies are possible. AKI can be a direct effect of the malignancy, a complication of the malignancy, or the consequence or side effect of chemotherapy. Nephrotic syndrome and glomerulonephritis, often presenting without overt kidney failure, have also been seen in all forms of leukemia and lymphoma. Lastly, the direct effects of the malignancy and complications from the tumor often result in numerous electrolyte disturbances and acid-base disorders, with life-threatening consequences if left untreated.
-
6.
Radiation therapy: retinal tumors.
Sethi, RV, MacDonald, SM, Kim, DY, Mukai, S
Developments in ophthalmology. 2013;:58-74
Abstract
The major retinal tumor that requires radiotherapy (RT) is retinoblastoma (RB); to a lesser degree, RT is used for some cases of retinal capillary hemangioma and lymphoma of the retina. Although there are concerns about the risk of RT-induced second malignancy in patients who carry a germline mutation in the RB1 gene, RT remains a very important part of our approach to intra-ocular and extra-ocular RB. Technical innovations in RT allow more precise targeting of retinal tumors and decreased exposure of adjacent normal tissue, an advance that is particularly significant for patients with hereditary RB who are at risk of additional malignancies.
-
7.
Cutaneous lymphomas: molecular pathways leading to new drugs.
Dummer, R, Goldinger, SM, Cozzio, A, French, LE, Karpova, MB
The Journal of investigative dermatology. 2012;(3 Pt 1):517-25
Abstract
Currently, cutaneous lymphomas represent a paradigm for the heterogeneity and the dynamic variability of neoplastic disorders resulting in the accumulation of clonal lymphocytes in the skin, and thus mirror the complexity of lymphocytic populations. Increasing knowledge and insight in pathobiology offer new opportunities for targeted interventions to selectively hit the tumor populations. mAbs, rexinoids, small kinase inhibitors, or molecules interfering with methylation or histone acetylation contribute to disease control. The rational and well-coordinated application of these tools, together with improved chemotherapeutic options, will hopefully further improve treatment success in the near future.
-
8.
Celiac disease and selected long-term health issues.
Freeman, HJ
Maturitas. 2012;(3):206-11
Abstract
Celiac disease is a genetically-based and immunologically-mediated systemic disorder, affecting primarily the small intestine in adults. About 0.5-1% of most populations studied are affected, with up to 2% in Finland. In families, specifically first-degree relatives, up to 20% may have the disease. Despite increased awareness among physicians and the public, celiac disease is still markedly under-diagnosed at all ages, including the elderly. Although serological screening is now widely used, celiac disease remains a biopsy-defined disorder, and a critical element to the correct diagnosis is documentation of a response to a gluten-free diet (since it is a gluten-sensitive disease). Sometimes, after the diagnosis has been established with a treatment response, changes re-appear and seem resistant to a gluten-free diet. Usually, poor or limited diet compliance, possibly from an unrecognized gluten source is responsible. In others, another superimposed cause, such as an infectious agent, could be important. Finally, another associated disease causing similar clinical and biopsy features or, alternatively, a complicating disorder may develop, such as a lymphoma. Some with biopsy features suggestive of celiac disease may not respond to a gluten-free diet. These may not have celiac disease at all, but instead, a sprue-like intestinal disease, or so-called unclassified sprue.
-
9.
Genetics of primary intraocular tumors.
Nagarkatti-Gude, N, Wang, Y, Ali, MJ, Honavar, SG, Jager, MJ, Chan, CC
Ocular immunology and inflammation. 2012;(4):244-54
-
-
Free full text
-
Abstract
Primary intraocular neoplasms are tumors that originate within the eye. The most common malignant primary intraocular tumor in adults is uveal melanoma and the second is primary intraocular lymphoma or vitreoretinal (intraocular) lymphoma. The most common malignant intraocular tumor in children is retinoblastoma. Genetics plays a vital role in the diagnosis and detection of ocular tumors. In uveal melanoma, monosomy 3 is the most common genetic alteration and somatic mutations of BAP1, a tumor suppressor gene, have been reported in nearly 50% of primary uveal melanomas. The retinoblastoma gene RB1 is the prototype tumor suppressor gene-mutations in RB1 alleles lead to inactivated RB protein and the development of retinoblastoma. Immunoglobulin heavy chain (IgH) or T-cell receptor (TCR) gene rearrangement is observed in B-cell or T-cell primary vitreoretinal lymphoma, respectively. Other factors related to the genetics of these three common malignancies in the eye are discussed and reviewed.
-
10.
The role of the transcription factor Miz-1 in lymphocyte development and lymphomagenesis-Binding Myc makes the difference.
Möröy, T, Saba, I, Kosan, C
Seminars in immunology. 2011;(5):379-87
Abstract
The Myc interacting zinc finger protein 1 (Miz-1) is a BTB/POZ domain containing transcription factor that can function as an activator or repressor depending on its binding partners. In a complex with co-factors such as nuclophosmin or p300, Miz-1 stimulates transcription of genes that encode regulators of cell cycle progression such as p21(Cip1) or p15(Ink4b) or inhibitors of apoptosis such as Bcl-2. In contrast, Miz-1 becomes a transcriptional repressor when it binds to c-Myc or Bcl-6, which replace nucleophosmin or p300. During lymphocyte development, Miz-1 functions as a regulator of the IL-7 signaling pathway at very early steps in the bone marrow and thymus. When the IL-7 receptor (IL-7R) recognizes its cognate cytokine, a cascade of events is initiated that involves the recruitment of janus kinases (JAK) to the cytoplasmic part of the IL-7R, the phosphorylation of Stat5, its dimerization and relocation to the nucleus, enabling a transcriptional programming that governs commitment, survival and proliferation of lymphoid lineage cells. Miz-1 is critical in this signal transduction pathway, since it controls the expression of Socs1, an inhibitor of JAKs and thus of Stat5 activation and Bcl-2 expression. A lack of Miz-1 blocks IL-7 mediated signaling, which is detrimental for early B- and T-lymphoid development. These functions of Miz-1 during early lymphocyte development are c-Myc-independent. In contrast, when c-Myc is constitutively over-expressed, for instance during c-Myc induced lymphomagenesis, the interaction between Miz-1 and c-Myc becomes important and critical for the initiation and maintenance of c-Myc-dependent lymphoid malignancies.